Analysis Of The Efficacy And Safety Of Immunotherapy Drugs In The Treatment Of Non-small Cell Lung Cancer

Objective: To evaluate and compare with the efficacy and safety of these three immune therapy drugs for non-small cell lung cancer, and to provide the reference for treatment and making decision in NSCLC.Methods: Relevant randomized controlled trials (RCTs) were searched in Cochrane Library, Web of Science and PubMed. RCTs of pembrolizumab (10mg/kg),nivolumab (3mg/kg) and atezolizumab (1200mg) for NSCLC were included. These included studies were analyzed by the Cochrane Collaboration’s RevMan 5.3 software.We compared with the efficacy and safety of the three drugs by Chi-square test and t-test.Results: The original search identified 749 articles in electronic database. We excluded 710 articles after review of the title and abstract. By assessing the accordance of the remaining articles with the predefined inclusion criteria, we excluded 27 articles after review of the article. Finally, 12 articles were considered eligible for inclusion in the meta-analysis. The ORR of pembrolizumab , nivolumab and atezolizumab were 17.94%,19.39% and 24.39%, respectively(P_=0.0065<0.01).The ≥ grade 3 AEs rate of nivolumab and atezolizumab were 10.84% and 33.47%,respectively(P_<0.001).Conclusion: Generally speaking, both nivolumab and atezolizumab were promising second-line drugs for NSCLC. They were well tolerated. Because of the limit of data we could not compare more results.